Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

Completed · Phase 2

Conditions studied: Non-Small Cell Lung Cancer (NSCLC)

In brief

The purpose of this study is to evaluate the effect of the ABT-869 on the NSCLC subjects.

Key facts

Study ID

NCT00517790

Run by

AbbVie (prior sponsor, Abbott)

People needed

140

Starts

2007-08-01

Expected to finish

2012-06-01

Last updated by the study team

2013-04-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject must be histologically or cytologically diagnosed with advanced or metastatic NSCLC
• Subjects must have at least one lesion measurable by CT scan as defined by RECIST
• The measurable lesion may have not received radiation therapy
• Subject has an Eastern Cooperative Oncology Group (ECOG) Performance status of 0-2
• Subject has received at least one prior line of systemic treatment but no more than two treatment regimen(s) for advanced or metastatic NSCLC. In addition, the subject may have received systemic neo-adjuvant or adjuvant chemotherapy for NSCLC
• Adequate organ function

You may not qualify if…

• Subject has received targeted VEGF/PDGF TKI (tyrosine kinase inhibitor) therapy. Prior Avastin is allowed.
• Subject has untreated brain or meningeal metastases.
• History of greater than 10% weight loss
• Subject has clinically relevant hemoptysis
• The subject has proteinuria CTC Grade > 1
• The subject currently exhibits symptomatic or persistent, uncontrolled hypertension defined as diastolic blood pressure > 100 mmHg or systolic blood pressure > 150 mmHg. Subjects may be re-screened if blood pressure is shown to be controlled with or without intervention.
• The subject has a documented left ventricular ejection fraction < 50%

Where it is running

• Site Reference ID/Investigator# 7194 — Fountain Valley, California, United States
• Site Reference ID/Investigator# 5617 — Los Angeles, California, United States
• Site Reference ID/Investigator# 7934 — Sacramento, California, United States
• Site Reference ID/Investigator# 5646 — Aurora, Colorado, United States
• Site Reference ID/Investigator# 6627 — Waterbury, Connecticut, United States
• Site Reference ID/Investigator# 7868 — Newark, Delaware, United States
• Site Reference ID/Investigator# 7616 — Port Saint Lucie, Florida, United States
• Site Reference ID/Investigator# 5648 — Chicago, Illinois, United States
• Site Reference ID/Investigator# 6739 — Evanston, Illinois, United States
• Site Reference ID/Investigator# 8100 — Harvey, Illinois, United States
• Site Reference ID/Investigator# 5269 — Indianapolis, Indiana, United States
• Site Reference ID/Investigator# 6042 — St Louis, Missouri, United States
• Site Reference ID/Investigator# 6680 — East Orange, New Jersey, United States
• Site Reference ID/Investigator# 5603 — Voorhees Township, New Jersey, United States
• Site Reference ID/Investigator# 5652 — Buffalo, New York, United States
• Site Reference ID/Investigator# 6184 — Charlotte, North Carolina, United States
• Site Reference ID/Investigator# 6777 — Greensboro, North Carolina, United States
• Site Reference ID/Investigator# 5650 — Memphis, Tennessee, United States
• Site Reference ID/Investigator# 6040 — Barrie, Canada
• Site Reference ID/Investigator# 5275 — Ottawa, Canada
• Site Reference ID/Investigator# 6572 — Toronto, Canada
• Site Reference ID/Investigator# 7756 — Marseille, France
• Site Reference ID/Investigator# 8068 — Toulouse, France
• Site Reference ID/Investigator# 8069 — Villejuif, France
• Site Reference ID/Investigator# 5660 — Singapore, Singapore

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.